{"id":18226,"date":"2022-07-28T17:19:49","date_gmt":"2022-07-28T11:49:49","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=18226"},"modified":"2022-07-28T17:20:39","modified_gmt":"2022-07-28T11:50:39","slug":"medtech-news-for-baxter-instylla-seegene","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-baxter-instylla-seegene","title":{"rendered":"AbbVie &#038; iSTAR\u2019S Strategic Alliance; Baxter Launches Welch Allyn RetinaVue 100 Imager PRO; Instylla\u2019S Embrace Hydrogel Embolic System; Primary Endpoint Met in the RADIANCE II US Trial; Roche&#8217;s Elecsys Amyloid Plasma Panel; EU Approval to Seegene\u2019s Allplex; SARS-CoV-2\/FluA\/FluB\/RSV Assay"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f2c4a5939a6\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f2c4a5939a6\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-baxter-instylla-seegene\/#ReCor_Medical_and_Otsuka_Medical_Devices_Announce_Primary_Endpoint_Met_in_the_RADIANCE_II_US_Pivotal_Trial_of_the_Paradise%E2%84%A2_System_for_the_Treatment_of_Hypertension\" >ReCor Medical and Otsuka Medical Devices Announce Primary Endpoint Met in the RADIANCE II US Pivotal Trial of the Paradise&#x2122; System for the Treatment of Hypertension<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-baxter-instylla-seegene\/#Seegene_to_Pave_Way_for_PCR_Testing_at_Local_Clinics_with_EU-approved_Multiplex_Test_and_Fully_Automated_PCR_Solution\" >Seegene to Pave Way for PCR Testing at Local Clinics with EU-approved Multiplex Test and Fully Automated PCR Solution<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-baxter-instylla-seegene\/#AbbVie_and_iSTAR_Medical_Announce_Strategic_Alliance_for_the_Treatment_of_Glaucoma\" >AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-baxter-instylla-seegene\/#Instylla_Announces_Positive_Results_from_Preclinical_Studies_of_Embrace%E2%84%A2_Hydrogel_Embolic_System_in_Haemorrhage_Models\" >Instylla Announces Positive Results from Preclinical Studies of Embrace&#x2122; Hydrogel Embolic System in Haemorrhage Models<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-baxter-instylla-seegene\/#Baxter_launches_Welch_Allyn_RetinaVue_100_Imager_PRO_in_South_Korea\" >Baxter launches Welch Allyn RetinaVue 100 Imager PRO in South Korea<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-baxter-instylla-seegene\/#Roches_Elecsys_Amyloid_Plasma_Panel_Granted_FDA_Breakthrough_Device_Designation_to_Enable_a_Timely_Diagnosis_of_Alzheimers_disease\" >Roche&#8217;s Elecsys Amyloid Plasma Panel Granted FDA Breakthrough Device Designation to Enable a Timely Diagnosis of Alzheimer\u2019s disease<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-recor-medical-and-otsuka-medical-devices-announce-primary-endpoint-met-in-the-radiance-ii-us-pivotal-trial-of-the-paradise-system-for-the-treatment-of-hypertension\"><span class=\"ez-toc-section\" id=\"ReCor_Medical_and_Otsuka_Medical_Devices_Announce_Primary_Endpoint_Met_in_the_RADIANCE_II_US_Pivotal_Trial_of_the_Paradise%E2%84%A2_System_for_the_Treatment_of_Hypertension\"><\/span><strong>ReCor Medical and Otsuka Medical Devices Announce Primary Endpoint Met in the RADIANCE II US Pivotal Trial of the Paradise&#x2122; System for the Treatment of Hypertension<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> July 26, 2022<\/strong>, <strong>ReCor Medical, Inc.,<\/strong> a completely owned subsidiary of <strong>Otsuka Medical Devices Co., Ltd.<\/strong>, with its headquarters in Palo Alto, California, a firm dedicated to revolutionizing the treatment of hypertension and Otsuka Medical Devices Co., Ltd., a fully owned subsidiary of Otsuka Holdings Co., Ltd. announced that the <strong>RADIANCE II US FDA IDE<\/strong> pivotal trial evaluating the <strong>Paradise&#x2122; Ultrasound Renal Denervation (uRDN)<\/strong> <strong>System <\/strong>as a treatment for hypertension met its primary efficacy endpoint, showing a statistically significant decrease in daytime ambulatory systolic blood pressure between treatment and a sham procedure measured at two months.<\/p>\n\n\n\n<p>The RADIANCE II US FDA IDE pivotal trial is a randomized, sham-controlled clinical trial of the ReCor Paradise uRDN System for treating patients with uncontrolled hypertension. At more than <strong>60 trial<\/strong> locations in <strong>8 countries<\/strong>, <strong>224 patients<\/strong> with mild-to-moderate uncontrolled hypertension who had previously been treated with up to two drugs were randomly assigned.<\/p>\n\n\n\n<p>The third and largest part of ReCor&#8217;s RADIANCE Global Program, RADIANCE II consists of randomized, sham-controlled trials assessing the Paradise uRDN System in hypertensive patients. The previously announced <strong>RADIANCE-HTN SOLO<\/strong> (conducted in patients with mild-to-moderate hypertension) and TRIO investigations are the first two in the series (conducted in those who remained hypertensive despite being on antihypertensive therapy). The primary effectiveness endpoints of both studies were met. ReCor currently has a third successful study with RADIANCE II, and the RADIANCE Global Program has randomized more than <strong>500 <\/strong>participants. The Global Paradise System (&#8220;GPS&#8221;) Registry, a real-world trial including up to <strong>3,000<\/strong> patients with uncontrolled hypertension, has also been started by ReCor.<\/p>\n\n\n\n<p>\u201c<em>Despite the truly formidable challenges of conducting a complex clinical trial in the throes of the COVID-19 pandemic, we are thrilled to observe these positive results of RADIANCE II, especially in light of those we have previously reported from RADIANCE-HTN SOLO and TRIO<\/em>,\u201d said Study Principal Investigators <strong>Ajay Kirtane,<\/strong> Professor of Medicine at Columbia University, Vagelos College of Physicians and Surgeons \/ NewYork-Presbyterian Hospital and Michel Azizi, Professor of Medicine at Universit\u00e9 Paris Cit\u00e9, H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France. \u201c<em>We cannot adequately convey our thanks to the patients, coordinators, and study physicians for their collective efforts, and we very much look forward to being able to present and publish the complete study details shortly<\/em>.\u201d<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/blood-pressure-monitoring-devices-market\"><strong>Blood Pressure Monitoring Devices Market<\/strong><\/a><strong>\u201d Report<\/strong>, the global blood pressure monitoring devices market was valued at <strong>USD 1.04 billion<\/strong> in 2021, growing at a <strong>CAGR of 10.68%<\/strong> during the forecast period from 2022 to 2027 to reach <strong>USD 2.10 billion<\/strong> by 2027. The blood pressure monitoring devices market is witnessing positive growth owing to various factors such as the increasing prevalence of hypertension, the surge in the geriatric population, the increasing <a href=\"https:\/\/www.delveinsight.com\/blog\/cardiovascular-disease-landscape\">prevalence of cardiovascular disease<\/a>, and technological advancements in product offerings. Therefore, the market for blood pressure monitoring devices is estimated to grow during the forecast period from 2022 to 2027.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-seegene-to-pave-way-for-pcr-testing-at-local-clinics-with-eu-approved-multiplex-test-and-fully-automated-pcr-solution\"><span class=\"ez-toc-section\" id=\"Seegene_to_Pave_Way_for_PCR_Testing_at_Local_Clinics_with_EU-approved_Multiplex_Test_and_Fully_Automated_PCR_Solution\"><\/span><strong>Seegene to Pave Way for PCR Testing at Local Clinics with EU-approved Multiplex Test and Fully Automated PCR Solution<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> June 29, 2022, Seegene Inc.<\/strong><strong>,<\/strong> South Korea\u2019s leading molecular diagnostics (MDx) firm, received EU approval for its <strong>Allplex&#x2122; SARS-CoV-2\/FluA\/FluB\/RSV Assay,<\/strong> which is compatible with the company\u2019s fully automated \u2018AIOS\u2019 (All-in-One System). This is expected to help small hospitals, local clinics, and public health centers effectively recognize COVID-19, influenza A and B, and respiratory syncytial virus (RSV).<\/p>\n\n\n\n<p>The Allplex&#x2122; SARS-CoV-2\/FluA\/FluB\/RSV Assay can find six targets associated with the four respiratory viruses. Three separate COVID-19 genes (S, RdRp, and N) are the targets to detect positive instances even when new variations appear consistently. Two internal controls are also used during the test to ensure adequate sampling and testing validity. Using no extraction, the product can produce results in just two hours, saving time and money.<\/p>\n\n\n\n<p>According to <strong>DelveInsight\u2019s \u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/molecular-diagnostics-market\"><strong>Molecular Diagnostics Market<\/strong><\/a><strong>\u201d Report<\/strong>, the global molecular diagnostic market was valued at <strong>USD 16.94 billion<\/strong> in 2021, growing at a <strong>CAGR of 9.16%<\/strong> during the forecast period from 2022 to 2027, to reach <strong>USD 28.44 billion<\/strong> by 2027. The increase in demand for molecular diagnostics is primarily attributed to the growing incidence of infectious diseases such as the sudden <a href=\"https:\/\/www.delveinsight.com\/covid19\">outbreak of COVID-19<\/a> and the rising burden of cancers across the globe. Moreover, rapid technological advancement in the molecular diagnostic product arena, increasing demand for point-of-care diagnostics, and rising consumer awareness regarding quick diagnostics, among others, are some of the key factors responsible for the molecular diagnostic market growth during the forecasted period.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-abbvie-and-istar-medical-announce-strategic-alliance-for-the-treatment-of-glaucoma\"><span class=\"ez-toc-section\" id=\"AbbVie_and_iSTAR_Medical_Announce_Strategic_Alliance_for_the_Treatment_of_Glaucoma\"><\/span><strong>AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> July 20, 2022, <\/strong><strong>AbbVie<\/strong><strong>,<\/strong> and<strong> iSTAR Medical SA<\/strong> announced a strategic transaction to develop further and commercialize iSTAR Medical&#8217;s MINIject\u00ae device, a minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma. This beneficial partnership will aid iSTAR Medical&#8217;s research, development, and marketing efforts for <strong>MINIject\u00ae <\/strong>and give AbbVie the chance to grow its eye care division by enhancing its glaucoma products, which already includes drops, sustained release implants, and stents.<\/p>\n\n\n\n<p>MINIject\u00ae is iSTAR Medical&#8217;s cutting-edge MIGS device for patients with primary open-angle glaucoma. MINIject\u00ae combines the distinctive porous structure of its proprietary STAR\u00ae material with the power offered by the supraciliary space. It is created to enhance the natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication while bio-integrating with surrounding tissue, preventing inflammation, fibrosis, and related complications.<\/p>\n\n\n\n<p>&#8220;<em>As a leading company in eye care with a commitment to a broad and diverse portfolio from the front to the back of the eye, along with our global footprint and infrastructure in glaucoma, we are well-positioned to support bringing these MIGS offering to patients and glaucoma specialists through this strategic alliance<\/em>,&#8221; said <strong>Michael Robinson, M.D, Vice President, Global Therapeutic Area Head of Eye Care, AbbVie<\/strong>. &#8220;<em>This alliance with iSTAR Medical is an important step as we continue to be an innovator in glaucoma by maximizing the value of interventional approaches throughout the treatment paradigm<\/em>.&#8221;<\/p>\n\n\n\n<p>According to<strong> DelveInsight\u2019s \u2018\u2018<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/minimally-invasive-surgical-mis-devices-market\"><strong>Minimally Invasive Surgical (MIS) Devices Market<\/strong><\/a><strong>\u201d Report,<\/strong> the global MIS devices market was valued at <strong>USD 28,873 million<\/strong> in 2021, growing at a <strong>CAGR of 7.38%<\/strong> during the forecast period from 2022 to 2027, to reach <strong>USD 42,499 million<\/strong> by 2027. The MIS devices market is witnessing positive market growth owing to the factors such as the rising prevalence of various cancers such as lung cancer which accounted for the highest number of cancer-related deaths and highest cancer incidence in 2021, and other indications such as cardiovascular diseases, and neurodegenerative diseases among others. Furthermore, the presence of factors such as growth in the aging population, wherein age plays a key role in the development of various indications, is another factor driving the growth of the MIS devices market. Moreover, the technological advancements in product development, such as the development of <a href=\"https:\/\/www.delveinsight.com\/blog\/medical-robots-market\">surgical robots<\/a>, are further driving the MIS devices market as new products are gaining regulatory approvals and are entering the market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-instylla-announces-positive-results-from-preclinical-studies-of-embrace-hydrogel-embolic-system-in-haemorrhage-models\"><span class=\"ez-toc-section\" id=\"Instylla_Announces_Positive_Results_from_Preclinical_Studies_of_Embrace%E2%84%A2_Hydrogel_Embolic_System_in_Haemorrhage_Models\"><\/span><strong>Instylla Announces Positive Results from Preclinical Studies of Embrace&#x2122; Hydrogel Embolic System in Haemorrhage Models<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> July 26, 2022, Instylla, Inc.,<\/strong> a privately held company developing next-generation liquid embolic for peripheral vascular embolotherapy, announced two publications that evaluated the <strong>Embrace&#x2122; Hydrogel Embolic System (HES)<\/strong> in preclinical porcine hemorrhage models.<\/p>\n\n\n\n<p>In a Journal of Vascular and Interventional Radiology (JVIR) publication, Dr. Gandras et al. evaluated the ability of Embrace HES to establish hemostasis in a porcine mesenteric artery hemorrhage model that mimics injury in humans. Results showed that <strong>100% <\/strong>of the damaged arteries were completely, quickly, and durably embolized by Embrace HES with a mean delivery time of <strong>5.3 minutes<\/strong>. Angiograms revealed no indication of non-target embolization.<\/p>\n\n\n\n<p>\u201c<em>Embrace was effective in achieving hemostasis in an animal haemorrhage model without evidence of non-target embolization. This next-generation liquid embolic has tremendous potential to play an important therapeutic role in a wide variety of clinical applications including haemorrhage and interventional oncology<\/em>,\u201d commented <strong>Dr. Eric Gandras, Associate Chief, Vascular and Interventional Radiology at North Shore University Hospital, New York<\/strong>, and lead author of the study.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s <strong>\u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-vascular-devices-market\"><strong>Peripheral Vascular Devices Market<\/strong><\/a><strong>\u201d Report<\/strong>, the global peripheral vascular devices market was valued at <strong>USD 9.63 billion<\/strong> in 2021, growing at a <strong>CAGR of 7.88%<\/strong> during the forecast period from 2022 to 2027, to reach <strong>USD 15.13 billion<\/strong> by 2027. The demand for peripheral vascular devices is primarily being boosted by the rapid growth in the <a href=\"https:\/\/www.delveinsight.com\/blog\/cardiovascular-disease-landscape\">prevalence of cardiovascular diseases<\/a> and peripheral vascular diseases, the approval of new and advanced products, and the rising incidence of lifestyle disorders such as diabetes and hypertension. Furthermore, the increase in the geriatric population is also likely to contribute to the peripheral vascular devices market growth.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-baxter-launches-welch-allyn-retinavue-100-imager-pro-in-south-korea\"><span class=\"ez-toc-section\" id=\"Baxter_launches_Welch_Allyn_RetinaVue_100_Imager_PRO_in_South_Korea\"><\/span><strong>Baxter launches Welch Allyn RetinaVue 100 Imager PRO in South Korea<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> July 25, 2022, Baxter<\/strong>, an American multinational health care company with headquarters in Deerfield, Illinois, launched its <strong>Welch Allyn RetinaVue 100 Imager PRO<\/strong> in South Korea.<\/p>\n\n\n\n<p>The device has been created to make diabetic retinopathy screening simple and inexpensive in primary care settings. The company stated that RetinaVue can double the patient compliance each year for potentially vision-saving annual Diabetic Retinal Exams (DREs). It enables healthcare professionals in primary care practices to capture high-quality fundus pictures with minimal training. The portable device enables comfortable retinal screening without pharmacological dilatation and features nonmydriatic capture through a <strong>3.0mm<\/strong> pupil. It uses integrated image-quality evaluation algorithms and patented touch less auto-focus\/image capturing technology to assist in minimizing the need for re-imaging visits. The tool immediately rates the quality of the taken image.<\/p>\n\n\n\n<p><strong>Baxter Asia-Pacific vice-president Bruce Peatey<\/strong> said: \u201c<em>Diabetes is an epidemic. Diabetic retinopathy is the leading cause of vision loss among adults 20-to-74 years of age, affecting 7.7 million people worldwide<\/em>\u201d.<\/p>\n\n\n\n<p>\u201c<em>It is simply tragic that a large percentage of patients with diabetes aren\u2019t being screened for diabetic retinopathy when it\u2019s one of the most preventable causes of blindness among adults<\/em>.<\/p>\n\n\n\n<p>\u201c<em>RetinaVue has the potential to change lives by helping to identify diabetic retinopathy in those individuals who had not previously been screened for the disease, enhancing the potential to save the sight of thousands, if not millions, of people with diabetes.\u201d<\/em><\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201d<a href=\"https:\/\/www.delveinsight.com\/report-store\/ophthalmic-imaging-equipment-market\"><strong>Ophthalmic Imaging Equipment Market<\/strong><\/a><strong>\u201d Report<\/strong>, the global Ophthalmic Imaging Equipment Market was valued at <strong>USD 2.33 billion<\/strong> in 2021, growing at a <strong>CAGR of 5.97%<\/strong> during the forecast period from 2022 to 2027 to reach <strong>USD 3.29 billion<\/strong> by 2027. The demand for ophthalmic imaging equipment is primarily being boosted by the rising <a href=\"https:\/\/www.delveinsight.com\/blog\/evolution-in-diabetes-management\">prevalence of diabetes<\/a> and growing geriatric population base, which has resulted in the increased prevalence of ocular diseases of different etiologies, increasing number of image-guided surgeries, and technical innovation in product development which is expected to increase in the product demand thereby contributing in the growth of the ophthalmic imaging equipment market during the forecast period from 2022-2027.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-roche-s-elecsys-amyloid-plasma-panel-granted-fda-breakthrough-device-designation-to-enable-a-timely-diagnosis-of-alzheimer-s-disease\"><span class=\"ez-toc-section\" id=\"Roches_Elecsys_Amyloid_Plasma_Panel_Granted_FDA_Breakthrough_Device_Designation_to_Enable_a_Timely_Diagnosis_of_Alzheimers_disease\"><\/span><strong>Roche&#8217;s Elecsys Amyloid Plasma Panel Granted FDA Breakthrough Device Designation to Enable a Timely Diagnosis of Alzheimer\u2019s disease<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> July 19, 2022, Roche Diagnostics,<\/strong> a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the <strong>Elecsys\u00ae Amyloid Plasma Panel<\/strong>.<\/p>\n\n\n\n<p>&nbsp;It is a cutting-edge novel method for enabling early Alzheimer&#8217;s disease detection. The Elecsys Amyloid Plasma Panel test examines and identifies biomarkers for Alzheimer&#8217;s disease in blood plasma to determine whether additional confirmatory testing for Alzheimer&#8217;s disease is necessary. For an Alzheimer&#8217;s blood-based biomarker test, Roche is the first in-vitro diagnostics firm to receive this designation.<\/p>\n\n\n\n<p>The Elecsys Amyloid Plasma Panel measures phosphorylated Tau (pTau) 181 protein assay and apolipoprotein (APOE) E4 assay in human blood plasma. Elevations in pTau occur in the early stages of Alzheimer\u2019s, while the presence of APOE E4 constitutes the most common genetic risk factor for Alzheimer\u2019s disease. The outcome is meant to be taken into account together with other clinical data to recommend further confirmatory testing using amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) testing. Patients who test negative on the Elecsys Amyloid Plasma Panel are probably not positive for amyloid and should be checked for other possible reasons of cognitive deterioration.<\/p>\n\n\n\n<p>\u201c<em>The key to transforming the lives of people with Alzheimer\u2019s disease is to diagnose as early as possible and intervene with the right care plans<\/em>,\u201d said <strong>Thomas Schinecker, CEO of Roche Diagnostics.<\/strong> &#8220;<em>Our new diagnostics test has the potential to streamline a patient&#8217;s journey, improving speed and access toward a confirmatory diagnosis, giving people with Alzheimer\u2019s disease and their caregivers more time to plan and prepare for the future<\/em>\u201d.<\/p>\n\n\n\n<p>According to <strong>DelveInsight\u2019s \u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/brain-monitoring-devices-market\"><strong>Brain Monitoring Devices Market<\/strong><\/a><strong>\u201d Report<\/strong>, the global Brain Monitoring Devices Market was valued at <strong>USD 6.31 billion<\/strong> in 2021, growing at a <strong>CAGR of 7.27%<\/strong> during the forecast period from 2022 to 2027, to reach <strong>USD 9.61 billion <\/strong>by 2027. The demand for brain monitoring devices is primarily being boosted by the rising prevalence of neurological diseases, technological advancement in product development, rising awareness about neurodegenerative diseases, and increasing brain monitoring applications in clinical trials. The growing demand for <a href=\"https:\/\/www.delveinsight.com\/report-store\/minimally-invasive-surgical-mis-devices-market\">minimally invasive devices<\/a> and the expanded therapeutic applications of brain monitoring devices are further expected to boost the brain monitoring devices market growth.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ReCor Medical and Otsuka Medical Devices Announce Primary Endpoint Met in the RADIANCE II US Pivotal Trial of the Paradise&#x2122; System for the Treatment of Hypertension On July 26, 2022, ReCor Medical, Inc., a completely owned subsidiary of Otsuka Medical Devices Co., Ltd., with its headquarters in Palo Alto, California, a firm dedicated to revolutionizing [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":18231,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[19400,19585,19146,19171,2753,17020,17021,16975,18799,19587,19586,420,19590,19591,19589,19188,19049],"industry":[17226],"therapeutic_areas":[17242,17233,17245,17244],"class_list":["post-18226","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-blood-pressure-monitoring-devices","tag-blood-pressure-monitoring-devices-market","tag-brain-monitoring-devices","tag-brain-monitoring-devices-market","tag-medical-device","tag-medical-devices","tag-medical-devices-market","tag-medtech-market","tag-medtech-news","tag-minimally-invasive-surgical-mis-devices","tag-molecular-diagnostics-market","tag-news","tag-ophthalmic-imaging-equipment","tag-ophthalmic-imaging-equipment-market","tag-peripheral-vascular-devices","tag-peripheral-vascular-devices-market","tag-surgical-robots","industry-medical-devices","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-hematological-disorders","therapeutic_areas-neurology","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News Updates | AbbVie, Baxter, Instylla, Roche, Seegene, ReCor<\/title>\n<meta name=\"description\" content=\"AbbVie &amp; iSTAR\u2019S Alliance; ReCor&#039;s RADIANCE II US Trial; Roche&#039;s Elecsys Amyloid Plasma Panel; Seegene\u2019s Allplex SARS-CoV-2 Assay; Baxter&#039;s\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-baxter-instylla-seegene\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News Updates | AbbVie, Baxter, Instylla, Roche, Seegene, ReCor\" \/>\n<meta property=\"og:description\" content=\"AbbVie &amp; iSTAR\u2019S Alliance; ReCor&#039;s RADIANCE II US Trial; Roche&#039;s Elecsys Amyloid Plasma Panel; Seegene\u2019s Allplex SARS-CoV-2 Assay; Baxter&#039;s\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-baxter-instylla-seegene\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-28T11:49:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-28T11:50:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/28171918\/MedTech-News-and-Updates-for-AbbVie-and-Baxter.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News Updates | AbbVie, Baxter, Instylla, Roche, Seegene, ReCor","description":"AbbVie & iSTAR\u2019S Alliance; ReCor's RADIANCE II US Trial; Roche's Elecsys Amyloid Plasma Panel; Seegene\u2019s Allplex SARS-CoV-2 Assay; Baxter's","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-baxter-instylla-seegene","og_locale":"en_US","og_type":"article","og_title":"MedTech News Updates | AbbVie, Baxter, Instylla, Roche, Seegene, ReCor","og_description":"AbbVie & iSTAR\u2019S Alliance; ReCor's RADIANCE II US Trial; Roche's Elecsys Amyloid Plasma Panel; Seegene\u2019s Allplex SARS-CoV-2 Assay; Baxter's","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-baxter-instylla-seegene","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-07-28T11:49:49+00:00","article_modified_time":"2022-07-28T11:50:39+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/28171918\/MedTech-News-and-Updates-for-AbbVie-and-Baxter.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-baxter-instylla-seegene","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-baxter-instylla-seegene","name":"MedTech News Updates | AbbVie, Baxter, Instylla, Roche, Seegene, ReCor","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-baxter-instylla-seegene#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-baxter-instylla-seegene#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/28171918\/MedTech-News-and-Updates-for-AbbVie-and-Baxter.png","datePublished":"2022-07-28T11:49:49+00:00","dateModified":"2022-07-28T11:50:39+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"AbbVie & iSTAR\u2019S Alliance; ReCor's RADIANCE II US Trial; Roche's Elecsys Amyloid Plasma Panel; Seegene\u2019s Allplex SARS-CoV-2 Assay; Baxter's","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-baxter-instylla-seegene"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-baxter-instylla-seegene#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/28171918\/MedTech-News-and-Updates-for-AbbVie-and-Baxter.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/28171918\/MedTech-News-and-Updates-for-AbbVie-and-Baxter.png","width":772,"height":482,"caption":"MedTech News and Updates for AbbVie and Baxter"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/28171918\/MedTech-News-and-Updates-for-AbbVie-and-Baxter-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Blood Pressure Monitoring Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Blood Pressure Monitoring Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Brain Monitoring Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Brain Monitoring Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech News<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Minimally Invasive Surgical (MIS) Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Molecular Diagnostics Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ophthalmic Imaging Equipment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ophthalmic Imaging Equipment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Peripheral Vascular Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Peripheral Vascular Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Surgical Robots<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Blood Pressure Monitoring Devices<\/span>","<span class=\"advgb-post-tax-term\">Blood Pressure Monitoring Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Brain Monitoring Devices<\/span>","<span class=\"advgb-post-tax-term\">Brain Monitoring Devices Market<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech News<\/span>","<span class=\"advgb-post-tax-term\">Minimally Invasive Surgical (MIS) Devices<\/span>","<span class=\"advgb-post-tax-term\">Molecular Diagnostics Market<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Ophthalmic Imaging Equipment<\/span>","<span class=\"advgb-post-tax-term\">Ophthalmic Imaging Equipment Market<\/span>","<span class=\"advgb-post-tax-term\">Peripheral Vascular Devices<\/span>","<span class=\"advgb-post-tax-term\">Peripheral Vascular Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Surgical Robots<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Jul 28, 2022","modified":"Updated on Jul 28, 2022"},"absolute_dates_time":{"created":"Posted on Jul 28, 2022 5:19 pm","modified":"Updated on Jul 28, 2022 5:20 pm"},"featured_img_caption":"MedTech News and Updates for AbbVie and Baxter","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/18226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=18226"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/18226\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/18231"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=18226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=18226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=18226"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=18226"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=18226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}